GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Launxp Biomedical Co Ltd (ROCO:6876) » Definitions » Debt-to-Revenue

Launxp Biomedical Co (ROCO:6876) Debt-to-Revenue : N/A (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Launxp Biomedical Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Launxp Biomedical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$1.30 Mil. Launxp Biomedical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$1.11 Mil. Launxp Biomedical Co's annualized Revenue for the quarter that ended in Dec. 2024 was NT$0.00 Mil.


Launxp Biomedical Co Debt-to-Revenue Historical Data

The historical data trend for Launxp Biomedical Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Launxp Biomedical Co Debt-to-Revenue Chart

Launxp Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
9.91 N/A N/A 240.73 0.97

Launxp Biomedical Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only N/A N/A 120.36 0.44 N/A

Competitive Comparison of Launxp Biomedical Co's Debt-to-Revenue

For the Biotechnology subindustry, Launxp Biomedical Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Launxp Biomedical Co's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Launxp Biomedical Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Launxp Biomedical Co's Debt-to-Revenue falls into.


;
;

Launxp Biomedical Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Launxp Biomedical Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.297 + 1.112) / 2.484
=0.97

Launxp Biomedical Co's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.297 + 1.112) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2024) Revenue data.


Launxp Biomedical Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Launxp Biomedical Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Launxp Biomedical Co Business Description

Traded in Other Exchanges
N/A
Address
10F, No. 51, Section 2, Gongyi Road, Nantun District, Taichung, TWN, 408
Launxp Biomedical Co Ltd is a company that researches, designs and develops Cancer drug rapid screening platform and Early development evaluation and technology licensing of generic drugs for cancer treatment. The company mainly focuses on the screening of development drugs, formulation of development strategies, project management, planning and execution of regulations and clinical trials, etc.

Launxp Biomedical Co Headlines

No Headlines